What is BLCO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BLCO?

P/E (TTM) is n/a and 52-week range is $14.44 to $18.91 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BLCO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BLCO?

The company profile lists revenue (TTM) near $5.33B, net income (TTM) near -$17.10B, EPS (TTM) near -$0.48 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Bausch + Lomb Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Vaughan, Ontario, CA, 357.4M shares outstanding, ISIN CA0717051076 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Bausch + Lomb Corp

$BLCO

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Employees

13,000

Website

ir.bausch.com/

IPO

2022-05-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NEW YORK STOCK EXCHANGE, INC.

ISIN

CA0717051076

Headquarters

Vaughan, Ontario, CA

Shares outstanding

357.4M

NAICS sector

Manufacturing

Institutional ownership

10.88%

Browse other companiesFree AI scores and summaries for more stocks